First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Fresenius Medical Care: the story is balanced — US Medicare reimbursement rate changes: Annual ESRD Prospective Payment System updates (typically 0-2% adjustments)…
★ Analysts see FY2027 revenue reaching $20.0B — +3.5% growth in a single year.
What Moves the Stock
1US Medicare reimbursement rate changes: Annual ESRD Prospective Payment System updates (typically 0-2% adjustments) directly impact 50%+ of service revenue
2Same-clinic patient census growth: Organic growth of 1.5-2.5% annually driven by aging demographics, diabetes/hypertension prevalence, and market share gains from independent clinics
3Commercial insurance mix: Commercial payers reimburse 3-4x Medicare rates; shift toward Medicare Advantage or loss of commercial patients materially impacts margins
4Labor cost inflation: Nursing and patient care technician wages represent 30-35% of clinic costs; wage pressure of 4-6% annually compresses margins without offsetting productivity gains
5International expansion and reimbursement: Growth in emerging markets (China, Middle East) and European rate negotiations (Germany's statutory health insurance adjustments)
6Dialysis Care Services (~75% of revenue): In-center hemodialysis treatments, home dialysis, and peritoneal dialysis across North America, EMEA, Asia-Pacific
7Dialysis Products (~25% of revenue): Hemodialysis machines, dialyzers, bloodlines, concentrates, and other consumables sold to third-party clinics and hospitals
value - Stock trades at 0.6x Price/Sales and 0.9x Price/Book with 11.8% FCF yield…
Rising rates increase financing costs on €5.8B net debt (mix of fixed and floating rate)…
Watch on earnings: US Medicare ESRD reimbursement rate announcements (published annually in November for following year), Same-clinic patient census growth rate (organic growth excluding acquisitions), Commercial insurance mix as percentage of total treatments (target 10-12% of US patient base).
One Sentence Summary:
Fresenius Medical Care: the story is balanced — us medicare reimbursement rate changes: annual esrd prospective payment system updates (typically 0-2% adjustments) directly impact 50%+.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.